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The guidance of endothelial cell organization into a capillary network has been a long-standing challenge in tissue engineering.
Some research eﬀorts have been made to develop methods to promote capillary networks inside engineered tissue constructs.
Capillary and vascular networks that would mimic blood microvessel function can be used to subsequently facilitate oxygen and
nutrient transfer as well as waste removal. Vascularization of engineering tissue construct is one of the most favorable strategies
to overpass nutrient and oxygen supply limitation, which is often the major hurdle in developing thick and complex tissue and
artiﬁcial organ. This paper addresses recent advances and future challenges in developing three-dimensional culture systems to
promote tissue construct vascularization allowing mimicking blood microvessel development and function encountered in vivo.
Bioreactors systems that have been used to create fully vascularized functional tissue constructs will also be outlined.
1.Introduction
Tissueengineeringisanemergingﬁeld.In1987,theNational
Science Foundation deﬁned tissue engineering as “an inter-
disciplinary ﬁeld that applies the principles of engineering
and the life sciences towards the development of biological
substitutesthatrestore,maintainorimprovetissuefunction”
[1]. Tissue engineering involve the repair and restoration of
various tissue and organ functions, while limiting host rejec-
tion and side eﬀects for the patient by delivering cells and/or
biomolecules through the use of 3D scaﬀolds [2].
Although there have been some successes to replace and
restore some tissues using tissue engineering approaches,
these have been mostly limited to thin or avascular tissues,
such as cartilage, skin, or bladder [2, 3]. However, for thick
and vascular tissues and for most organs, the lack of a suﬃ-
cient supply of nutrients and oxygen to growing tissues, as
well as the waste removal, represent two important factors
that limit the successful development and implantation of
engineered tissue constructs [4]. These issues of poor mass
transportandmasstransferhaveoftenledtothefailureofthe
culture process or even to that of implants.
One possible strategy for creating thick engineered tissue
substitutesinvitroistouseabioactiv escaﬀoldthatallowsthe
guidanceofendothelialcellspromotingmicrovesseldevelop-
mentinadirectionalfashioninordertovascularizethetissue
construct [5]. It is quite well accepted among the scientiﬁc
community that prevascularization of tissue construct ap-
pearstobeoneofthemostfavorableandeﬃcientapproaches
to address the problem of tissue survival due to a lack of oxy-
gen and nutrient supply [6]. The concept of prevasculariza-
tion mainly involves the incorporation of endothelial cells
into a bioactive scaﬀold to form a capillary network inside
the structure prior to its implantation [7]. This could accel-
erate the formation of functional microvessels within the
core of an implant.
The idea of using prevascularized engineered tissue sub-
stitutes was ﬁrst suggested by Mikos et al. (1993) when com-
paring the performance of prevascularized tissues to nonvas-
cularized ones. Later, Sakakibara et al. (2002) concluded that2 The Scientiﬁc World Journal
prevascularization enhanced the beneﬁts of cardiomyocyte
transplantation [6, 8]. More recently, Levenberg et al. (2005)
demonstrated that prevascularization improved the perfor-
manceofskeletalmuscletissueconstructswhenimplantedin
mice [9]. Furthermore, studies aiming to induce and control
vascularization may also advance general knowledge on the
development of therapeutics targeting angiogenesis. Numer-
ous pathological conditions are associated with insuﬃcient
oxygen and blood supply [2, 10]. Also, uncontrolled angio-
genesis is associated with many diseases, including rheuma-
toid arthritis, macular degeneration, and tumour growth
[11].
Advances in tissue engineering have brought signiﬁcant
knowledge on the mechanisms and parameters related to
vascularization and angiogenesis development and blood
microvessel network formation [11, 12]. This paper will re-
port status of the current research and development related
to cell culture systems designed to promote angiogenesis and
vascularization. It is necessary to improve our understanding
of the mechanisms behind angiogenesis and to apply that
k n o w l e d g et og u i d em i c r o v e s s e lg r o w t hi no r d e rt os u p p o r t
the development of artiﬁcial organs. Other aspects including
thechallengesinangiogenesisguidance,assessmentofangio-
genesis and lumen formation, and the use of bioreactor sys-
tem to culture vascularized tissue constructs will also be out-
lined.
2. CellTypesand Markers
Cells can be isolated from a patient or donor and seeded into
as c a ﬀold to allow cell proliferation and support prevascu-
larization process [6, 13]. Subsequently, these constructs can
be implanted in the same patient. After implantation, hope-
fully endothelial cells would develop connections with the
existing blood microvessels of the surrounding tissue, form-
ing a microvascular network and allowing adequate tissue
perfusion [13].
When tissues become thicker, cells located more than a
few hundred microns (about 200 to 300μm) from capillaries
suﬀer from a lack of oxygen and nutrients, resulting into
necroticconditions[14].Currently,thedevelopmentofthick
and complex tissues and organs such as the heart, muscles,
kidneys, liver, and lung relies, in part, on the knowledge and
ability to stimulate microvascular network formation within
tissue constructs. Therefore, knowing how to carry out cell
seeding within a scaﬀold and to perform successful in vitro
cultures to prevascularize tissue constructs prior to their im-
plantation is highly important. As such, researchers rely on
the increasing knowledge related to neovascularization (i.e.,
vasculogenesis and angiogenesis) process to stimulate vascu-
lar network formation within three-dimensional tissue con-
structs [12, 14].
Blood vessels are composed of several cell types and the
main ones are smooth muscle cells (SMCs), pericytes, ﬁbro-
blasts, and endothelial cells. Smooth muscle cells are found
in blood vessels, such as in middle layer (i.e., tunica media)
of large and small blood vessels, in lymphatic vessels, uterus,
and in the gastrointestinal and respiratory systems. Behind
the basic function of vascular SMC in blood vessels, that is,
to maintain vessels integrity and support the endothelium,
they are highly specialized cells for the regulation of blood
vessel diameter, vessel contraction, blood pressure, and ﬂow
distribution[15].Furthermore,SMCssynthesizetheconnec-
tive tissue matrix of the vessel wall, which is composed of
elastin, collagen, and proteoglycans. There are some markers
to identify smooth muscle cells, including smooth muscle
α-actin (SMαA), smooth muscle myosin heavy chain (SM-
MHC) [15], SM22α, and calponin [16]. To date, SMαA is the
most commonly used marker of SMC, which represents up
to 70% of the actin population in vascular SMC.
Pericytesareperivascular-speciﬁccellsthatareassociated
with capillaries and blood microvessel development. Peri-
cytes have the capacity to diﬀerentiate into other cell types,
including SMC, ﬁbroblasts, and osteoblasts [17]. During
blood microvessel development, the coverage of capillary by
pericytes is important for the maturation, remodeling, and
maintenance of the vascular system via the secretion of
growth factors and/or modulation of the ECM. The impor-
tant role of pericytes in capillary development in vitro has
been studied by some researchers [17, 18]. For example,
endothelial cells cocultured with pericytes, separated by
a cellulose membrane, resulted in inhibition of capillary
growth, while when pericytes were in contact or close to
endothelial cells, endothelial cell growth and capillary devel-
opment were observed [19].
Fibroblasts are a cell type mostly found in connective tis-
sues, including blood vessels, cartilage, soft tissues (e.g., der-
mis), and bone. A connective tissue can be deﬁned as a tissue
that wraps, connects, nourishes, and supports all other tis-
sues and organs [20]. Fibroblasts originate from mesenchy-
mal cells—mesenchymal cells are progenitor cells capable to
form connective tissues and the lymphatic system [21]. Dur-
ing normal development and wound-healing process of con-
nective tissues, ﬁbroblasts produce ﬁbres and secrete factors
to maintain the ECM and provide structural support for the
tissues. To date, ﬁbroblasts from human skin or skin ﬁbro-
blasts have been cocultured with endothelial cells in many
angiogenesis studies [18, 19, 22, 23]. Also, 3T3 cells that were
originally obtained from Swiss mouse embryo tissues have
become a standard ﬁbroblast cell line [18]. In an in vitro
study, skin ﬁbroblasts have been reported to have a signif-
icant eﬀect over microvascular formation and angiogenesis
development from HUVEC [22, 23].
In the entire circulatory system, endothelial cells are
liningontheinnerlayerofthevessels(i.e.,tunicaintima)and
consist of more than 1013 cells for approximately 1kg of
vessel [24]. The ﬁrst culture of endothelial cells was reported
by Shibuya around 1930, and then various techniques and
sourcesofendothelialcellswereinvestigated[25].Forinvitro
studies, endothelial cells from animal or human sources can
be used. Endothelial cells from animals include canine jug-
ular endothelial cells and aortic endothelial cells either from
bovine (BAEC), porcine (PAOEC), or rat (RAOEC) sources.
Human endothelial cells include human umbilical vein
(HUVEC), human dermal microvascular (HDMEC), and
human vascular (HVEC) [25]. Since endothelial cells from
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and due to the available sources of endothelial cells, HUVEC
have been utilized by many research groups [24, 26].
Heterogeneity between endothelial cells has been report-
ed not only between large vessel-derived cells and those of
microvascular origin, but also between organs [24, 25]. For
example, aortic endothelial cells are thicker and cover a small
area compared to those from human pulmonary artery [27].
Also, endothelial cells from microvascular (e.g., human der-
mal microvascular endothelial cells (HDMECs)) are elon-
gated, while those from human umbilical vein (HUVEC) are
polygonal [27, 28].
Furthermore, endothelial cells derived from arteries are
diﬀerent than those isolated from veins. In arteries, endothe-
lial cells are long and narrow, aligned in the direction of
blood ﬂow, and form a continuous endothelium with many
tight junctions. Endothelial cells from veins are shorter and
wider and not aligned in the direction of blood ﬂow [29].
These heterogeneities reﬂect their diﬀerence in functionality
intermofthereleaseofvasoactivesubstancesandtheirinter-
action with leucocytes during normal vessel development
and wound healing [28, 29].
Some unique molecular markers as well as genes are pre-
ferentiallyexpressedbyendothelialcells.Forexample,theex-
pression of CD31 (also known as platelet endothelial cell ad-
hesionmolecule-1orPECAM-1),CD34,andvonWillebrand
factor (vWF), as well as dil-acetylated LDL uptake has been
used in many studies to distinguish endothelial cells from
other cell types [29, 30]. Also, cell adhesion molecules
(CAM), such as ICAM-1 (intercellular adhesion molecule-
1), VCAM-1 (vascular cell adhesion molecule-1), and E- and
P-selectins can be used to identify endothelial cells during
wound healing and angiogenesis [30, 31].
Other cell-cell adhesive proteins, such as ESAM (endo-
thelial cell selective adhesion molecule), VE-cadherin (vas-
cular endothelial cadherin), and N-cadherin, are known to
have a signiﬁcant in angiogenesis regulation [27, 30]. ESAM
is a tight junction molecule that is responsible for the regu-
lation of cellular permeability and for maintaining the polar-
ityofendothelialcells,whileVE-cadherinisanadherensjun-
ction molecule that plays an important role in regulating cell
growth and in the organization of new vessels during angio-
genesis [30–32]. Another member of the cadherin family, N-
cadherin is localized on the basal side of endothelial cells.
During vessel maturation, N-cadherin is in contact with per-
icytes or smooth muscle cells [32].
Furthermore, the expression of some genes to assess if
endothelial cells are undergoing angiogenesis has been sug-
gested. Some genes that are preferentially expressed during
endothelial cell sprouting, lumen formation, and capillary
network establishment are HESR-1, notch 1, notch 4, and
delta 4 [23, 33].
3. Vasculogenesis andAngiogenesis
Recent studies on blood microvessels have provided essential
information to develop strategies allowing neovasculariza-
tion. Microvessels can develop through two processes: vascu-
logenesis and angiogenesis. Both can be potentially applied
to vascularize tissue constructs. Although in some papers
both terms are often used to mean the same thing and are
simply referred to as angiogenesis; the speciﬁc role of the
microenvironmental factors and the overall mechanisms are
diﬀerent [34].
Vasculogenesis refers to the process of diﬀerentiation of
endothelial progenitor cells (i.e., mesodermal, mesenchymal,
or bone marrow cells) to form new blood vessels. For exam-
ple, in dermal tissues, vasculogenesis occurs in three main
steps: (1) diﬀerentiation of mesodermal cells into angioblasts
or hemangioblasts; (2) diﬀerentiation of angioblasts or hem-
angioblasts into endothelial cells; (3) the organization of new
endothelial cells into a primary capillary plexus [34, 35].
Angiogenesis can occur in two diﬀerent ways: (1) intus-
susceptive, the longitudinal splitting of existing vessels, and
(2) sprouting angiogenesis, the outgrowth of a new branch
from a preexisting vessel [36]. Compared to the intussuscep-
tive angiogenesis that mostly occurs during new organ for-
mation as well as during tumour development, sprouting
angiogenesis is relatively well characterized [36]. Sprouting
angiogenesis refers to the formation of new capillaries from
preexisting blood vessels, which is mainly initiated by a
sprouting process [36, 37].
Angiogenesis involves four diﬀerent stages: (1) endothe-
lial cells interact with their ECM and the underlying base-
ment membrane; (2) they proliferate, migrate, and commu-
nicate with each others; (3) they form cell-cell connections
and tube-like structures; (4) tube sprouting and remodelling
occur to form microvessels containing multicellular lumen
[37].
Angiogenesis as well as the availability of the numerous
models now existing has been pioneered about 30 years ago
byFolkmanandHaudenschild(1980)whentheydemonstra-
ted that new capillary blood vessels form in tumor progres-
sion. They observed that capillary tube formation was ini-
tiated from a vacuole structure within the endothelial cells
thatsubsequentlydevelopmulticellularcapillarylumen[38].
Morerecently,Kuceraetal.(2007)haveproposedthreemod-
els explaining how tube-like structures developed during the
vascularization process: (1) cell death and phagocytosis, (2)
Wrapping of the spaces around the extracellular matrix, and
(3) vacuole formation from the coalescence of intracellular
vacuoles. The models are presented on Figure 1, and below
are the details [39].
3.1. Cell Death and Phagocytosis Model. Some in vitro as well
as in vivo studies of angiogenesis report that lumen forma-
tionwasassociatedwithapoptoticandcelldeathevents.This
modelproposedsomestepsofthevascularlumenformation:
endothelial cells organize themselves into a multicellular
cord, and cells in the middle of the cord become apoptotic
and die [40]. Finally, endothelial cells at the edge phagocytise
the apoptotic cells, subsequently forming a multicellular ves-
sel containing lumen [40, 41]. According to this model,
dead cells deﬁne the lumen of the tube-like structures
(see Figure 1(a)). However, this model fails to explain how
the tube-like structures continue their formation into a
continuous vessel.4 The Scientiﬁc World Journal
Apoptosis Phagocytosis
and exocytosis
Lumen
Lumen
development
(a)
Elongation Closure and
lumen formation
Lumen
(b)
Vacuole
Lumen
Membrane
invagination
Vacuole
formation
Vacuole fusion and
lumen development
Extracellular matrix
Endothelial cell
Apoptotic cell
(c)
Figure 1: Models of the development of tube-like structures during vasculogenesis.
3.2. Wrapping Spaces around ECM Model. This model main-
ly suggests that most capillaries are initiated by the elonga-
tionofendothelialcellstoopenmulticellularstructures.Sub-
sequently, vascular tube can form when the elongated cell
sheets are closed, even without vacuole formation (see
Figure 1(b)). This concept was initiated by Hirakow and
Hiruma (1983), when they studied the development of vas-
cularlumenmadeofendothelialcellswithouttheevidenceof
vacuole-like structures [42] .I nar e c e n ts t u d y ,P a r k e re ta l .
(2004)haveshownthatthevasculardevelopmentwasinitiat-
ed by the proliferation and migration of endothelial cells to
form a cord-like structure, and vascular cords then undergo
tubulogenesis to form vessels containing lumen [43]. How-
ever, this model does not explain the polarity of endothelial
cells during the development of capillary structures.
3.3. Vacuole Formation from the Coalescence of Intracellular
Vacuoles. The idea behind this model was proposed by
Folkman and Haudenschild (1980) when explaining angio-
genesis and lumen formation within 3D constructs. This
model involves several steps: formation either of single or
multiple vacuole(s) inside the endothelial cells and vacuoles
subsequently fuse with each others. Finally, a continuous
multicellular lumen will form when two or more cells with
their vacuoles adhere to each others, therefore fusing (see
Figure 1(c))[ 38].
More recent, Davis et al. (2000) have reported that endo-
thelial cell lumens were forming in three-dimensional colla-
gen and ﬁbrin matrices. The authors reported that this pro-
cess was controlled by the formation and coalescence of
intracellular vacuoles and in the absence of cellular junctions
[44]. Furthermore, the expression of cytoskeletal regulators
controlling various cellular functions of endothelial cells,
such as Cdc42 and Rac1 GTPases, were involved in morpho-
genesis and vascularization processes [44, 45].
Even though this model can explain the role of vacuoles
in capillary tube structure and lumen formation, some ques-
tions remain, such as how endothelial cells compensate their
basal side during the vacuole coalescence and vacuole fusion
and how the apical-basal polarity of endothelial cells can be
established during tube stabilization [38, 46] .S i n c en o n eo f
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observed during vascular tube development, it can thus be
hypothesized that all these three models can be combined, in
some way, to explain observations made in angiogenesis and
vasculogenesis assays [46, 47].
4. Promoting Angiogenesisin
Three-DimensionalConstructs
During vasculogenesis and angiogenesis development, cell-
cell as well as cell-ECM interactions are complex. While the
roles of some individual factors during neovascularization
have been investigated, the optimum combination between
cell and their ECM can signiﬁcantly vary from one material
to another [48]. Therefore, some strategies have been pro-
posed to promote and direct angiogenesis in 3D environ-
ments.
Endothelial cells have been cultured in various matrices
that have been precoated or not with adhesive matrix pro-
teins or cell binding peptides. Surface chemistry and the im-
mobilization mode can aﬀectprotein conformation, orienta-
tion and anchorage strength, thus inﬂuencing cell behaviour
[48].Formationofcapillary-likestructuresmadeofendothe-
lial cells depends on the particular biological environment
that will direct cell-cell as well as cell-biomaterial adhesion
strength, which relies on biochemical and mechanical signals
[49]. To date, there are three major strategies that have been
usedtostudyhowbiomaterialspropertiesaﬀectangiogenesis
formation: (1) micropatterning, (2) surface modiﬁcation,
and (3) extracellular matrix modiﬁcations [48, 49].
4.1. Micropatterning. Photolithography, micromoulding,
and microprinting are some examples of techniques used in
micropatterning. Among them, laser microcontact printing
is the most frequently studied [50]. It is a process in which
biological molecules are printed directly onto a scaﬀold sur-
face, and it has been broadly utilized by tissue engineering
scientists. For example, a poly(ethylene glycol)-diacrylate
(PEGDA) hydrogel, known to resist protein adsorption, has
been micro-printed with the cell adhesive ligand, Arg-Gly-
Asp-Ser (RGDS) in diﬀerent concentrations and using diﬀe-
rent patterns. Endothelial cells were cultured on these RGDS
patternsandenhancedtube-likestructureformationwasob-
served on 50μm-wide stripes [51].
Inanotherstudy,microcontactprintingwasusedtoform
various patterns of ﬁbronectin molecules on gold. Endothe-
lial cells cultured on these ﬁbronectin patterns formed tub-
ular structures on 10μm-wide lines of ﬁbronectin [52]. In a
diﬀerent study, when coated with gelatin, 20μm lines pro-
moted endothelial cells to undergo capillary morphogenesis
[53].However,applyingthistechniqueto3Dscaﬀoldsispro-
blematic.
4.2. Surface Modiﬁcation. Proteins such as ﬁbronectin, gela-
tin, collagens, and ﬁbrinogen, only to name a few, have been
used to coat synthetic polymers to increase their surface bio-
activity. For example, collagen coating on the surface of elec-
trospun poly(L-lactic acid)-co-poly(ε-caprolactone) scaﬀold
increased endothelial cell adhesion and spreading [54, 55].
Collagen type I has been known to increase the number of
tube-like structures made of endothelial cells, thus support-
ing angiogenesis and vasculogenesis in in vitro experiments
[56]. Furthermore, the proteolytic cleavage of collagen type
IV provides an important binding site for endothelial cells
undergoing angiogenesis in vitro [57].
Gelatinisusedbymanyresearchgroupstopre-coattissue
culture dishes. In tissue engineering, gelatin was used to coat
poly(glycolic acid) (PGA) scaﬀold for the controlled release
ofsomeangiogenicgrowthfactors[58]. When PGA scaﬀolds
covered by bFGF- and VEGF-containing gelatin hydrogel
were implanted in mice, signiﬁcant angiogenic eﬀect was
observedattheimplantedsite[59,60].Furtherclinicaltestto
treat diabetic foot ulcer using gelatin matrix to release bFGF
conﬁrmed that the matrix allowed better wound healing
[60].
Fibronectin has been investigated in many studies and
found to enhance endothelial cell adhesion and spreading
[61]. Fibronectin also supports the formation of focal adhe-
sion and induces the organization of actin ﬁlaments into
stress ﬁbre via the interaction with its main receptor, that is,
α5β1a n dαvβ3[ 61, 62]. Furthermore, the lack of ﬁbronectin
during vascular development caused an abnormality in the
vascular formation in mice [63].
Another protein, ﬁbrinogen, has been incorporated in
poly(ethylene glycol) (PEG) hydrogels and it found to in-
creasethebioactivityofthescaﬀoldbyenhancingendothelial
cell and SMC adhesion [64]a sw e l la sm e s e n c h ym a ls t e mc e l l
adhesion [65]. Furthermore, ﬁbrinogen has many binding
sites for endothelial cells. Also, ﬁbrin gel binds many growth
factors and bioactive cloth components [65, 66]. Therefore,
theuseofﬁbrin(ogen)tomodifybiomaterialssurfacesandto
encapsulate cells in tissue engineering applications is of im-
portance.
In other strategies, polymer surfaces can be precoated
with cells to increase the bioactivity of the scaﬀold. For ex-
ample,expandedpoly(tetraﬂuoroethylene)(ePTFE)waspre-
coated with bladder carcinoma cells before being implanted
in mice. This strategy stimulated angiogenesis and neovas-
cularization in ePTFE vascular grafts [67]. In a more recent
study, precoated PET ﬁbres with HUVEC allowed the guid-
ance of the angiogenesis process and subsequent micro-vas-
cularization in ﬁbrin. No microvessel structures were obser-
ved when uncovered ﬁbres were utilized [68].
4.3. ECM Modiﬁcation. The interaction between cells and
their matrix is very complex, since there are many proteins
and soluble molecules (including growth factors) present in
the ECM. These molecules interact with cells through diﬀer-
entcell-bindingdomains.Inbloodvesseldevelopment,there
are approximately 20 angiogenic growth factors, and among
themvascularendothelialgrowthfactor(VEGF),basicﬁbro-
blast growth factor (bFGF), platelet-derived growth factor
(PDGF), and angiopoietin-1 (Agp-1) which are the most fre-
quently studied [69].
In in vitro angiogenesis assays, growth factors can be
added to the culture media and/or immobilized in the ECM.
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on the development of tube-like structures and on microves-
sel maturation [70]. For example, endothelial cells cultured
in type I collagen gels with culture media supplemented
with ﬁbroblast growth factor-2 (FGF-2), vascular endothelial
growth factor (VEGF), and phorbol ester formed tubes con-
taining lumens, which have similar structure to microvessels
found in vivo [69]. In the absence of growth factors and
phorbol ester, the vascular tube structures did not form
[71]. Other in vitro angiogenesis studies showed that growth
factors added to culture media can promote sprouting,
lumen formation, and better vessel stability [72, 73].
Growth factors are often bound to the ECM and can be
released upon interaction with cells [74], as well as immobi-
lized to the ECM that was used to carry out the culture [75].
In this approach, growth factors can be released, as encoun-
teredinvivo.Forexample,VEGFwascovalentlyimmobilized
into type I collagen gel [76]. Using the chicken chorioallan-
toic membrane (CAM) assay, this collagen matrix was found
toinducecapillaryformationandtissueingrowth.Also,basic
ﬁbroblast growth factor (bFGF) was immobilized into poly-
(ethyleneglycol)(PEG)hydrogelstoguidecellalignmentand
migration [77].
As many cellular processes observed during vasculogene-
sisrequirenumeroussignallingpathwaysandgrowthfactors,
recent research eﬀorts have been focusing on the sequential
delivery of multiple growth factors [78]. For example, the
sequential delivery of VEGF and PDGF-BB (platelet-deri-
ved growth factor-BB) in a controlled-release polymer de-
vice made of poly(lactic glycolic) (PLG) (85:15 lactide:gly-
colide) induced a mature vascular network covered by
smooth muscle cells [79]. Other results also concluded that
one growth factor alone is not suﬃcient to create mature and
stable vasculature [80].
4.4. Coculture Systems and Microvessel Maturation. Achiev-
ing microvessel maturation and stabilization during blood
microvessel development represents another challenge fol-
lowing vascular tube formation by endothelial cells. This is
often referred to as angiogenesis remodelling. Angiogenesis
remodelling is the process by which primary vascular tubes
or immature vessels are modiﬁed to form an interconnecting
branching network, yielding to microvessel structure stabili-
zation [74, 81]. During this phase, tube-like structures made
of endothelial cells and containing lumens recruit other sup-
porting cells, such as pericytes and smooth muscle cells
(SMCs), to form a close wall and mature blood microvessels
[82].
Furthermore, in the vascular tree, endothelial cells are
liningontheinnerlayerofthevesselwall(tunicaintima)and
supported by other cell types [81, 82]. While immature ves-
sels consist of tube structures made of endothelial cells, capi-
llaries consist of tubes made of endothelial cells covered by
pericytes and a basement membrane [82]. In arterioles and
venules, vascular SMC cover large area and are closely asso-
ciated with the endothelium basement membrane.
Therefore, co-culture systems seem to be appealing to re-
create the real microvessel environment and to achieve more
mature microvessels. For example, smaller number of vessel-
like structures containing lumens was found when endothe-
lial cells were cultured alone in PLLA-PLGA (50:50) scaf-
folds, compared to samples cocultured with ﬁbroblasts [83].
Vascularized engineered skeletal muscle tissue constructs
have been successfully produced by Levenberg et al. using
a multiculture system of myoblasts (progenitor cells of the
muscle cells), ﬁbroblasts, and endothelial cells into this
PLLA-PLGA scaﬀold [83, 84]. In more recent result, cocul-
turing HUVECs with skin ﬁbroblast was signiﬁcantly im-
proved the maturation of microvessels structure in a 3D en-
vironment [85, 86].
5. Bioreactors to SupportVascularization
Many tissue engineering scientists believe that the next
generation of functional tissue replacements truly needs the
use of bioreactors, in which the culture conditions (e.g., pH,
temperature, O2 concentration, pressure, pulsation, nutrient
transfer,andwasteremoval,etc.)canbeadjustedandstudied
to ﬁnd the optimal mechanical, chemical, and biological sti-
muli for a given application [87]. In addition, bioreactor
operations will provide a rational basis for the structural and
functional design of engineered tissues for the use as model
systems to reduce time of innovation, discovery, and produc-
tion in biological and clinical research [87, 88]. Also, the use
ofbioreactorsshouldacceleratethedevelopment,evaluation,
and delivery of engineered tissue products to patients [89].
To date, there are various types of bioreactors that have
been designed and tested and these diﬀer from the appli-
cations involved. For example, bioreactors have been used
to support the growth of cartilage [90–92], bone [93, 94],
cardiac [95, 96], ligament [97], and heart valve [98]t i s s u e s .
Furthermore,therearesometypesofbioreactorsthatcan
be used in large tissue cultures, and these include the con-
tinuous stirred-tank reactor (CSTR), hollow ﬁber reactors,
and the slow turning lateral vessel (STLV) reactor [88], only
to name a few. CSTR reactors are designed to mix oxygen
and nutrients within the culture medium and to reduce the
boundary layer at the scaﬀold surface [99]. Hollow ﬁbre re-
actors consist of a chamber perfused with semipermeable
ﬁbres ﬁlled with culture medium. Often, cells are located in
the extracapillary space of the chamber. In the past years,
this type of reactor was used to produce proteins made by
mammalian cells, and to expand mammalian cells in vitro
[100, 101]. STLV reactor was proposed by NASA (National
Aeronautics and Space Administration) at the Johnson Space
Center (USA) for earth-based as well as space experiments
[101].
In the context of vascularization and blood microvessel
development, ideally the bioreactor should enable to control
basic environmental parameters such as the dissolved oxy-
gen concentration, pH, and temperature, as well as tissue
factors including cellular structures and function [102]. For
example, the system should allow the transport of nutrients
and oxygen from the reservoir to the cell location within the
scaﬀold. As it has been long known, the maximum tissue
thickness achievable by diﬀu s i v et r a n s p o r ta l o n ei sa p -
proximately 1mm. The optimization of scaﬀold material
properties as well as the design of bioreactor chamber is
therefore of upmost importance [103].The Scientiﬁc World Journal 7
Bioreactors can also enable control over the mechanical
stimulation for cellular guidance inside the scaﬀold in order
to improve tissue vascularization. As endothelial cells are
lining theinner surfaceofbloodvesselsoftheentirecapillary
and circulatory system, they experience ﬂuid shear stress and
dynamic ﬂow conditions [103]. Therefore, the use of a dyn-
amic culture system can allow some cell mechanical stimula-
tion prior to the use of the grown tissue construct [103, 104].
Dynamic culture parameters such as pulsation, pressure,
and ﬂow rate that mimic in vivo conditions often result in
better cellular organization as well as mechanical properties
of the tissue constructs when compared to constructs cultur-
ed in static environment [105, 106]. To date, several studies
of endothelial cell monolayers have revealed that cell orien-
tation reﬂects the direction of the ﬂow [107, 108]. Also, in
endothelial cells,shear stress-increased VEGF, and PDGF-BB
expression compared to those cultured in static conditions
[109]. In addition, pulsatile ﬂow can improve structural or-
ganization of SMC and this is an essential step in the vas-
cularization process [110, 111].
6. Concluding Remarks
Overthepastyears,signiﬁcantadvancesintissueengineering
research have provided hope for the commercial availability
of human bioartiﬁcial organs. More simple engineered tissue
substitutes(e.g.,skin,bone,andcartilage)havebeensuccess-
fully applied and implanted, while for more complex and
vascularized constructs, many problems still remain before
tissuesubstitutescanbeavailable.Consequently,strategiesto
develop engineered tissue constructs that enhance vasculari-
zation inside become important. This will provide an impro-
vement of oxygen and nutrient transfer as well as waste re-
moval that could allow production of thicker tissue substi-
tutes as well as artiﬁcial organs. Tissue engineering research
relies on the increasing knowledge of angiogenesis and vas-
culogenesis mechanisms occurring during capillary tube for-
mationandbloodmicrovesseldevelopment.Furthermore,to
overcome the bottleneck of the complex interplay between
various factors inﬂuencing tissue vascularization, the use of
bioreactor system is necessary.
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